non-interventional study (NIS)
Showing 1 - 25 of >10,000
A Prospective, Non-interventional, Long-term, Post-Authorisation
Not yet recruiting
- Growth Hormone Deficiency
- No intervention
- (no location specified)
Mar 8, 2023
Connective Tissue Disease-associated Interstitial Lung Diseases
Not yet recruiting
- Lung Diseases, Interstitial
- (no location specified)
Apr 6, 2023
(NIS) on Sodium-glucose Co-transporter-2 Inhibitors Use in
Not yet recruiting
- Diabetes Mellitus, Type 2
- Sodium/glucose cotransporter-2 inhibitors (SGLT2i)
- (no location specified)
May 22, 2023
(NIS) on Effectiveness in ND-CKD SHPT Patients
Not yet recruiting
- Chronic Kidney Disease
- (no location specified)
Jul 12, 2022
Learn About the COVID-19 Prescribed Paxlovid in Morocco
Not yet recruiting
- COVID-19 Drug Treatment
- (no location specified)
Aug 15, 2023
DESTINY Breast Respond HER2-low Europe
Not yet recruiting
- Unresectable Breast Cancer
- +2 more
- Trastuzumab deruxtecan
- (no location specified)
Jul 6, 2023
Health-related Quality of Life After Switching COPD Patients
Recruiting
- Pulmonary Disease, Chronic Obstructive
- Spiriva® Respimat®
- +2 more
-
Liestal, SwitzerlandCantonal Hosp. Baselland,Univ.Med.Dept,Liestal
Jan 9, 2023
Participants Receiving Nivolumab in Adjuvant Setting for
Active, not recruiting
- Melanoma
-
Lille, FranceLocal Institution
Mar 17, 2022
PROVIDENCE - Real-world Study in HER2-positive Unresectable or
Not yet recruiting
- Breast Neoplasms
- +2 more
- (no location specified)
Oct 7, 2022
Retrospective NIS to Evaluate the Patient Benefit of TES
Active, not recruiting
- Retinitis Pigmentosa
- Transcorneal Electrostimulation via OkuStim System
-
Heidelberg, Germany
- +3 more
May 17, 2022
Learn More About Iberogast Advance in the Real-world Setting
Recruiting
- Functional Gastrointestinal Disorders Such as Irritable Bowel Syndrome and Functional Dyspepsia
- +2 more
- Iberogast (STW5-II, BAY98-7410)
-
Multiple Locations, Many Locations, GermanyMany Locations
Jan 16, 2023
Oncology, Epidemiology, Breast Cancer Trial in East Of Algeria, Middle Of Algeria, Ouest Of Algeria/ Oran Region (NIS (Non
Completed
- Oncology
- +2 more
- NIS (Non Interventional Study) observational study
-
East Of Algeria, Algeria
- +2 more
Jun 3, 2022
HER2-positive Advanced Gastric Cancer, HER2-positive Gastroesophageal Junction Adenocarcinoma Trial (Trastuzumab deruxtecan)
Not yet recruiting
- HER2-positive Advanced Gastric Cancer
- HER2-positive Gastroesophageal Junction Adenocarcinoma
- Trastuzumab deruxtecan
- (no location specified)
Aug 11, 2023
A NIS of Alpelisib in Combination With Fulvestrant in
Not yet recruiting
- Hormone Receptor Positive HER2 Negative Breast Cancer With a PIK3CA Mutation
- Alpelisib
- Fulvestrant
- (no location specified)
Aug 9, 2022
Ovarian Cancer, Hereditary Ovarian Cancer Syndrome Trial in Germany
Completed
- Ovarian Cancer, Hereditary Ovarian Cancer Syndrome
-
Amberg, Germany
- +67 more
Jan 9, 2023
Nivolumab Monotherapy or in Combination With Ipilimumab in
Active, not recruiting
- Melanoma
-
Essen, GermanyLocal Institution
Apr 25, 2022
Nivolumab Plus Chemotherapy in First Line Treatment of Adult
Recruiting
- Gastric Cancer
-
Hamburg, GermanyLocal Institution
Feb 24, 2022
(NIS) Collecting Experiences For IPF in Taiwan
Completed
- Pulmonary Fibrosis
-
Changhua, Taiwan
- +9 more
Mar 19, 2021
Impact of Mayzent on aSPMS Patients in a Long-term NIS in Italy
Recruiting
- Active Secondary Progressive Multiple Sclerosis
- siponimod
-
Ancona, AN, Italy
- +19 more
Dec 27, 2022
Satisfaction and Usability of DuoResp® SPIROMAX® in Asthma and
Completed
- Patient Satisfaction
- Budesonide, Formoterol Fumarate Dihydrate
-
Berlin, GermanyTeva Investigational Sites
Nov 5, 2021
Dermatitis, Atopic Trial in Germany
Recruiting
- Dermatitis, Atopic
-
Bramsche, Germany
- +7 more
May 23, 2022
(NIS) of Nivolumab With or Without Ipilimumab in Advanced Kidney
Recruiting
- Renal Cell Carcinoma
- +5 more
-
Paris, France
- +1 more
Feb 23, 2021
s in Patients With Relapsing Multiple Sclerosis
Recruiting
- Relapsing Multiple Sclerosis
- ofatumumab
- +2 more
-
Untermeiting, Bayern, Germany
- +35 more
Aug 12, 2022
Natural History of Netherton Syndrome
Not yet recruiting
- Netherton Syndrome
- (no location specified)
Jun 21, 2023